Lipid Nanoparticle– tag –
-
VERVE-101 Achieves 53-69% LDL-C Reduction in Lipid Disorder Trials, Accelerating LNP-Based Gene Editing Therapeutics
PMC (Part of MDPI) Switzerland Overview VERVE-101, an in vivo base editing therapy targeting PCSK9 via mRNA-LNP delivery, has progressed to clinical trials (NCT05398029) for lipid disorders, showing significant LDL-C reductions of 53% to... -
Bispecific Antibody-Conjugated Lipid Nanoparticles Achieve Cell-Specific mRNA Delivery, Overcoming Liver Tropism
ACS Publications USA Overview Researchers have developed a bispecific antibody-conjugated lipid nanoparticle (TbsAb-LNP) platform designed for precise, cell-specific mRNA delivery, effectively circumventing the inherent liver tropism of ... -
Drexel Symposium Highlights Injectable Self-Healing Hydrogels for Therapeutic Treg Induction and Strategies to Mitigate LNP-Induced Inflammation
Drexel University USA Overview A symposium at Drexel University showcased the development of injectable self-healing granular hydrogels optimized for inducing therapeutic regulatory T cells (Tregs), with modified B7x demonstrating dose-d... -
Lipid Nanoparticles (LNP) Overcome Nucleic Acid Respiratory and Gastrointestinal Mucosal Delivery Barriers, Opening New Avenues for Disease Treatment
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are playing a crucial role in significantly enhancing the effectiveness of nucleic acid delivery to respiratory and gastrointestinal mucosa. LNPs have emerged as an effective strategy ... -
Lipid Nanoparticles (LNP) Establish Success in COVID-19 Vaccines as Cutting-Edge Technology Essential for mRNA, siRNA Delivery
Inside Therapeutics International Overview Lipid nanoparticles (LNPs) are a cutting-edge nano-drug delivery system designed to protect and efficiently deliver nucleic acids, particularly mRNA and siRNA, to target cells. Through the succe... -
Machine Learning Accelerates Lipid Nanoparticle (LNP) Design, Dramatically Boosting Efficiency and Speed in Therapeutic Molecule Delivery
Pharmatica International Overview While lipid nanoparticles (LNPs) are crucial for protecting and safely transporting therapeutic molecules like mRNA and siRNA to target cells, their design is inherently complex. Researchers have success... -
CREATE Medicines Expands Targeted In Vivo CAR Platform via Monash University Partnership, Driving Cell-Type-Specific Delivery with Advanced LNP Technology
BioSpace Australia Overview CREATE Medicines has expanded its targeted in vivo CAR platform through a strategic research collaboration and exclusive license agreement with Monash University. This partnership leverages targeted lipid nano... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e...
